Skip to main content

Table 7 Clinical features of AFF cases published in the literature

From: Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy: a retrospective study and systematic review

Journal Age/Gender Primary disease Exposure to other BMA Duration of denosumab treatment Diagnosis Operation (treatment)
Yang et al. The oncologist (2017) 70/F Breast Ca. Alendronate, Risedronate 23 months Rt. AFF Intramedullary rod placement
Ota et al. Breast Cancer (2017) 73/F Breast Ca. Zoledronic acid 54 months Bilateral AFF  
Sugihara et al. Clin Nucl Med (2018) 59/F Breast Ca. None 4 years (48 months) Rt. impending AFF or AFSR  
Koizumi et al. Clin Nucl Med (2017) 53/F Thyroid Ca. Bisphosphonate 1.5 years (18 months) Lt. impending AFF  
Tateiwa et al. Journal of orthopaedic surgery (2017) 52/F Breast Ca. Pamidronate, Zoledronate 2 years and 3 months (27 months) Bilateral AFF Intramedullary nail was placed
Austin et al. Acta Orthopedica (2017) 75/F Breast Ca.
None 2 years (24 months) Bilateral AFF Intramedullary fixation
86/M Prostate Ca. None 3.5 years (42 months) Rt. AFF